American multinational healthcare and pharmaceutical corporation.
“Johnson & Johnson said it's leaning toward spinning off its orthopedics unit, after having reportedly been in talks to sell it for around $20b to Apollo.”
“Link Cell Therapies, CAR-T developer using marker-combination activation, raised a $30 million Series A round led by Johnson & Johnson with BMS participation.”
Source→“Link Cell Therapies raised an additional $30 million for its Series A led by Johnson & Johnson.”
Source→“Apollo — PE firm in talks to buy DePuy Synthes from J&J for ~$20B”
“Raised $85M Series C led by Johnson & Johnson; represents growing institutional pharma interest in psychedelic-adjacent therapeutics without the regulatory complexity of hallucinogens.”
Source→“Delix Therapeutics, a Boston-based developer of psychoplastogens, raised $85m in Series C funding led by J&J.”
“Johnson & Johnson is investing $785m into Sail Biomedicines, a Cambridge, Mass.-based CAR-T cell therapy developer formed by Flagship Pioneering, via a deal that also gives J&J an acquisition option.”
“Johnson & Johnson agreed to buy Firefly Bio, an SF-based biotech focused on protein degraders, for $1b in cash.”
“Momentum shows up in named pharma partnerships (Novartis, Lilly, Johnson & Johnson), a mix of partnered and wholly owned programs, and the company's push to move internal assets toward the clinic.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.